Search Results
Jan 13, 2026, 08:00 ET Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
TH41Human iPSC-Derived Oligodendrocytes Implicate Maturation Deficits in Neuropsychiatric Disease
More news about: Johnson & Johnson
Jan 12, 2026, 09:30 ET Trailhead Biosystems Expands Financing to $40 Million
conditions to generate iPSC-derived cells that closely match the molecular and functional properties of primary human cells.Advancing Product Development and Human-Relevant Cell ModelsThe additional financing will enable Trailhead to further develop its portfolio of iPSC-derived human cell
More news about: Trailhead Biosystems Inc
Jan 07, 2026, 08:50 ET Aspen Neuroscience Appoints Chief Commercial Officer Lisa Johnson-Pratt, M.D. and Welcomes Revati Shreeniwas, M.D., FCCP as Chief Medical Officer to Accelerate Late‑Stage Development and Commercial Readiness
transition into the role of Chief Commercial Officer (CCO). These moves strengthen Aspen's late‑stage development and commercial readiness for its autologous iPSC‑derived cell therapy for Parkinson's disease.
More news about: Aspen Neuroscience, Inc.
Jan 06, 2026, 13:27 ET Aperture Therapeutics Announces First-In-Class MMP9 Antisense Oligonucleotide Program for ALS
MMP9-targeting ASOs capable of achieving robust knockdown of MMP9 mRNA and protein while attenuating inflammatory biomarkers implicated in ALS pathology in human iPSC-derived microglia. To enable translational pharmacology studies, the company developed a proprietary humanized MMP9 knock-in mouse model expressing
More news about: Aperture Therapeutics
Jan 06, 2026, 11:00 ET Novoron Bioscience Awarded $2.5 Million NIH/NIA SBIR Grant to Accelerate Alzheimer's Drug Discovery with Human Brain Organoids
Many Alzheimer's programs fail because traditional laboratory models cannot reflect the complexity of the human brain. Novoron's platform uses human iPSC-derived cortical organoids that capture realistic cell interactions and synaptic networks. This creates a more predictive setting for early drug discovery
More news about: Novoron Bioscience
Jan 06, 2026, 10:30 ET Cell Culture Reagents Market worth $8.95 billion by 2030 | MarketsandMarkets™
growth factors and cytokines are repeatedly used for cell activation, expansion, and differentiation. Adoption is also rising in stem cell, organoid, and iPSC workflows, where defined growth-factor cocktails are essential for consistent outcomes.Request Sample Pages@
More news about: MarketsandMarkets
Jan 05, 2026, 08:00 ET Kenai Therapeutics Receives $8M Grant from California Institute for Regenerative Medicine (CIRM) to Advance RNDP-001 for Treatment of Idiopathic Parkinson's Disease
clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions. By leveraging a proprietary, Nobel Prize-winning iPSC platform, Kenai is developing off-the-shelf, allogeneic neuron replacement and gene-modified cell therapies designed to be disease-modifying. Kenai's
More news about: Kenai Therapeutics/BIOCOM
Dec 26, 2025, 09:01 ET From Follower to Force: China's Biotech Sector Enters the Global Clinical Mainstream
shared translational and clinical data from iPSC-derived cardiomyocyte programs, highlighting China's advancement of cell therapies into rigorously designed, multinational clinical development.HELP's lead program, HiCM-188, is the world's first iPSC-derived regenerative therapy for advanced heart
More news about: HELP Therapeutics
Dec 17, 2025, 08:00 ET The Colossal Foundation Doubles Funding to $100 Million to Prevent Mass Extinctions
have identified a single nucleotide change that can confer this resistance and have successfully generated the first induced pluripotent stem cell (iPSC) line for the species, a major step toward producing toxin-resistant quolls. This foundational achievement represents a critical advance in protecting
More news about: The Colossal Foundation
Dec 15, 2025, 08:00 ET Kenai Therapeutics Announces First Patient Dosed in Phase 1 REPLACE™ Clinical Trial of Neuron Replacement Cell Therapy RNDP-001 for Idiopathic Parkinson's Disease
Inc. is a leading developer and manufacturer of human iPSCs and iPSC-derived cells utilized in drug discovery, contract development and manufacturing services for cell therapies. For its partners, FUJIFILM Cellular Dynamics utilizes its iPSC platform to advance the progress of therapeutic candidates in
More news about: Kenai Therapeutics/BIOCOM
Dec 14, 2025, 19:22 ET Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
or SR–aGvHD cases. Historical two-year survival rates in patients with SR–aGvHD are less than 20%.[1]Cynata's Cymerus™ iPSC[2]-derived MSC[3] product for intravenous use, CYP-001, is designed to modulate the immune system and improve both response rates and survival
More news about: Cynata Therapeutics
Dec 08, 2025, 18:19 ET The Jackson Laboratory receives an up to $30 million contract award to revolutionize drug safety testing with AI-powered "virtual hearts"
expertise in high-resolution imaging of tiny mouse hearts; Paul Robson, a stem cell biology expert and a lead developer of the genetically varied human iPSC panel; and Travis Hinson, a cardiologist whose lab investigates inherited conditions leading to heart failure. They are joined by Daniel Paull of NYSCF,
More news about: The Jackson Laboratory
Dec 02, 2025, 10:18 ET Cellipont Bioservices Expands Manufacturing Capabilities with New Ballroom-style Cleanroom and 50-liter Single-use Bioreactor to Advance Cell Therapy Production
major milestone in Cellipont's continued investment to meet the growing demand for advanced manufacturing of exosome, induced pluripotent stem cell (iPSC), and mesenchymal stem cell (MSC) therapies.
More news about: Cellipont Bioservices
Dec 02, 2025, 06:00 ET bit.bio Publishes 2025 Sustainability Report
ioCells™ portfolio of human iPSC-derived products accelerate the global shift from animal testing to human-relevant research modelsPlatinum Green Impact Award and new lab efficiency protocols deliver measurable, year-on-year sustainability improvementsMale and female
More news about: bit.bio
Dec 02, 2025, 06:00 ET bit.bio Publishes 2025 Sustainability Report
ioCells™ portfolio of human iPSC-derived products accelerate the global shift from animal testing to human-relevant research models Platinum Green Impact Award and new lab efficiency protocols deliver measurable, year-on-year sustainability improvements Male and female
More news about: bit.bio
Dec 01, 2025, 06:00 ET Morphocell Technologies Completes US$50 Million Series A Financing
Technologies is a Montreal-based regenerative medicine company developing stem cell–derived tissue and organ replacement therapies. Its proprietary iPSC-derived platform supports a broad pipeline of tissue-engineered solutions targeting severe organ dysfunctions, with liver disease as its first focus.
More news about: Morphocell Technologies
Dec 01, 2025, 06:00 ET Morphocell Technologies chiude un round di Serie A da 50 milioni di dollari
tessuti ingegnerizzati derivati da cellule staminali per la sostituzione funzionale di tessuti e organi. La sua piattaforma proprietaria basata su cellule iPSC sostiene un ampio pipeline di soluzioni ingegnerizzate mirate alle disfunzioni d'organo più gravi, con un focus iniziale sulle malattie del fegato.
More news about: Morphocell Technologies
Nov 24, 2025, 10:01 ET Regenerative Medicine Market to Skyrocket to USD 403.86 Billion by 2032 Driven by Cell & Gene Therapy Breakthroughs, Stem Cell Advancements, and Multi-Indication Expansion
22% YoY under fast-track programsStem-cell therapy adoption increased 14% in musculoskeletal and dermatology careJapan's iPSC-based R&D investment exceeded USD 1.8 billion in 2024More than 100 regenerative medicine clinical trials active across major
More news about: DataM Intelligence 4 Market Research LLP
Nov 20, 2025, 08:00 ET ALS Network and ALS United Announce New Research Grantees
Sandra Almeida, PhD, University of Massachusetts Chan Medical School, Department of Neurology for Investigation of TDP-43 Dysfunction in an iPSC-Based Three-Dimensional Multicellular Model of C9ORF72-ALS/FTD. Frederick Arnold, PhD, Washington
More news about: ALS Network
Nov 20, 2025, 07:02 ET Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
Scale manufacturing capabilities to meet clinical and future commercial demand. Advance Aspen's pipeline of autologous iPSC-derived therapies for additional neurological indications. Aspen's proprietary manufacturing platform
More news about: Aspen Neuroscience, Inc.
Nov 15, 2025, 11:00 ET BrainXell Showcases Pioneering iPSC Research and Promising In Vivo Data for BXT-110 for Parkinson's Disease at the 2025 Society for Neuroscience Annual Meeting
be presented during poster sessions at the 2025 Society for Neuroscience (SfN) Annual Meeting in San Diego, highlighting new breakthroughs in human iPSC-derived cell models and regenerative neuroscience.
More news about: BrainXell, Inc
Nov 08, 2025, 08:34 ET 피죤, CIIE 2025서 '둥지' 주제로 혁신적 수유•유아 돌봄 과학 공개
통찰력은 오늘날 피죤이 글로벌 비즈니스의 방향을 설정하는 데 큰 도움을 주고 있다." 올해 피죤의 중국 스킨케어 연구센터(Skincare Research Center)는 노벨상 수상 연구를 기반으로 한 iPS 세포 기술로 개발된 iPSc 추출 신생아 표피 피부 모델을 선보였다. 아기 피부 관리 분야의 오랜 과제인 민감한 유아 피부에 대한 제품 효능을 과학적으로 검증하는 이 모델은 현재 피죤만의 독자적인 제형 개발 및 테스트에 활용되고 있으며, 2025년 피죤의 주력 제품으로 선보인 베르닉스 베이비
More news about: Pigeon
Nov 07, 2025, 08:00 ET Shinobi Therapeutics Announces the Appointment of Dr. Laurent Fischer as Chair of its Board of Directors
Biotechnologies, recently acquired by Eli Lilly Shinobi prepares to advance two immune evasive iPSC therapies toward the clinic in 2026, and today announces its first data presentation at the upcoming Society for Immunotherapy of Cancer (SITC) Annual
More news about: Shinobi Therapeutics
Nov 07, 2025, 07:06 ET Pigeon Showcases Parenting Innovations Under "The Nest" Theme at CIIE 2025
capabilities, and insights are helping to shape our global business." This year, Pigeon's Skincare Research Center in China debuted an iPSc derived infant epidermal skin model for infants, engineered with iPS cell technology derived from Nobel Prize-winning research. The model addresses
More news about: Pigeon
Nov 03, 2025, 11:03 ET BrainXell Therapeutics Unveils Promising Preclinical Data Demonstrating Efficacy of BXT-110, an Autologous iPSC-Derived Neuronal Therapy, in Parkinson's Disease
"As a company, we are innovators in iPSC technology, and this represents an important advancement for BrainXell Therapeutics," said Katherine Vega Stultz, CEO. "Our data presentations reflect our commitment to rigorous science, innovation and deep expertise in iPSC biology and neuronal differentiation.
More news about: BrainXell, Inc.